ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00002873
Recruitment Status : Completed
First Posted : September 2, 2004
Last Update Posted : July 19, 2013
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Radiation Therapy Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2007
  Study Completion Date : No date given
Publications of Results:
Rabinovitch R, Winter K, Taylor M, et al.: Toxicity and cosmesis from RTOG 95-17: a phase I/II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma. [Abstract] Breast Cancer Res Treat 106 (1): A-4078, S192-3, 2007.
Arthur DW, Winter K, Kuske RR, et al.: A phase II trial of brachytherapy alone following lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-51, S29-30, 2006.
Kuske RR, Winter K, Arthur DW, et al.: A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517. [Abstract] J Clin Oncol 22 (Suppl 14): A-565, 18s, 2004.
Kuske RR, Winter K, Arthur D, et al.: A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95-17. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-151, 87, 2002.